Status:
COMPLETED
Safety and Tolerability of Single and Multiple Doses of VAK694 in Healthy and Atopic Subjects
Lead Sponsor:
Novartis
Conditions:
Allergic Rhinitis
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
Brief Summary
This study will evaluate the safety and tolerability of single and multiple doses of VAK694 in healthy volunteers and otherwise healthy volunteers with a history of allergies.
Eligibility Criteria
Inclusion
- History of allergic rhinitis (Part 2 only)
Exclusion
- Very low or high body weight
- Heavy or recent smoker
- Exposure to human monoclonal antibodies
- Other protocol-defined inclusion/exclusion criteria may apply.
Key Trial Info
Start Date :
October 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2008
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT00620230
Start Date
October 1 2007
End Date
April 1 2008
Last Update
September 27 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigator Site
North Miami Beach, Florida, United States, 33169